NF1-PN Care

Real Patient Living with NF1-PN

You can help patients stay engaged in their care​

I am fortunate to have a neurologist who treats adult patients with neurofibromatosis.

– Krista, living with NF1-PN

Many specialties are involved in NF1-PN care

Given the complex clinical presentation of neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN), a multidisciplinary team (MDT) of treaters may include primary care providers (PCPs), neurologists, oncologists, geneticists, surgeons, neuropsychiatrists, and eye specialists.1

In a study of 130 adult NF1 cases2,*:

26 different specialties

were involved in care across all patients

Median of 2 specialists

were involved with each patient (range: 0-6)

Real Patient Living with NF1-PN
Pediatric patients who are treated in neurofibromatosis (NF) clinics generally have an MDT working together to diagnose, monitor, and treat their NF1-PN.3
For young adult patients outside a clinic, the added responsibility of coordinating their own appointments, in addition to managing travel and financial barriers, can cause them to disengage from care.3-5,†
If you’re caring for a patient, talk to them about the importance of keeping up with their NF1-PN care as they enter adulthood. Earlier detection of changes in PNs can lead to earlier management.6,7

“I remember seeing my pediatrician a couple weeks before leaving for college. He checked me out and told me to take care of myself. That was it.”

– Antwan, living with NF1-PN

Tips to help patients transition between pediatric and adult care

Discuss the transition of care early to help patients prepare8

Refer patients to healthcare providers (HCPs) who are within driving distance of where patients live4,8

If there are no local specialists where the patient primarily resides, you may want to work to establish a local HCP (eg, PCP) who can monitor them in conjunction with a specialist in another town4

Work with the patient to discuss practical concerns (eg, travel barriers, insurance)8

Work with care coordinators, if possible9

“As I transitioned from pediatric into adult care, I was constantly having conversations with my doctors about next steps and routine tests they should be having done.”

– Krista, living with NF1-PN

Considerations to help patients stay engaged in their NF1-PN care​

Stressing the importance of routine monitoring

  • Remind patients that monitoring is a vital part of staying on top of their NF1-PN and about why having a local HCP who can monitor them in between specialty appointments is so important6,7,10
    • Even if there are no acute symptoms, a PN may be growing or transforming into a malignant peripheral nerve sheath tumor (MPNST). Once a PN has transformed into an MPNST, mortality risk greatly increases (5-year overall survival is 35% to 50%)11-13
  • During an annual physical exam that includes blood and lab work, patients should be assessed for signs and symptoms, including pain, mobility issues, and changes in size, volume, or texture of tumors6
Helping patients stay engaged in their NF1-PN care.
Factors that should be considered for monitoring intervals include age, tumor location, presence of PN morbidity, imaging appearance, and growth rate. Scanning intervals should be shortened upon change in imaging appearance or new symptoms. There is no consensus on appropriate intervals for monitoring in NF1-PN. Monitoring intervals ranged from 3 to 24 months in a survey of 30 NF1 experts.10

Maintaining an open and ongoing dialogue with patients

  • At every appointment, it is helpful to ask patients about any symptoms they may be experiencing, particularly pain, mobility issues, and visible changes in their tumors6
  • Check in with patients to see if they are experiencing depression or anxiety related to their condition6
  • Encourage patients to tell you about the different ways their lives have changed due to their NF1-PN
  • Engage in shared decision-making with patients so they can take an active role in their health and NF1-PN management; check in about practical concerns such as financial and travel barriers
  • Encourage engagement with other patients through advocacy groups14
  • The use of telemedicine can alleviate travel burden and allow you to maintain regular check-ins15

Additional resources​​

Tools are available for your patients and your practice.

Based on a retrospective case-control study of all adult cases of NF1 among 4.06 million medical records in a Pacific Northwest population. One hundred twenty-two case charts were reviewed to ascertain NF1 disease features, comorbidities, and severity of disease.2
Based on SpringWorks Therapeutics–sponsored market research that included 4 adult NF1-PN patients and 11 NF1-PN caregivers. Both patients and caregivers were asked to identify the emotional and experiential impact of NF1-PN on patients.5
  1. Armstrong AE, Belzberg AJ, Crawford JR, Hirbe AC, Wang ZJ. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas. BMC Cancer. 2023;23(1):553.
  2. Gregory TA, Molina PSB, Phillips GD, Henson JW. Impact of neurofibromatosis type 1 in an adult community population. Neurooncol Pract. 2022;9(3):229-235.
  3. Radtke HB, Berger A, Skelton T, Goetsch Weisman A. Neurofibromatosis type 1 (NF1): addressing the transition from pediatric to adult care. Pediatric Health Med Ther. 2023;14:19-32.
  4. Rietman AB, van Helden H, Both PH, et al. Worries and needs of adults and parents of adults with neurofibromatosis type 1. Am J Med Genet A. 2018;176(5):1150-1160.
  5. Data on file: SpringWorks Therapeutics, Inc.
  6. Stewart DR, Korf BR, Nathanson KL, Stevenson DA, Yohay K. Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018;20(7):671-682.
  7. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44(2):81-88.
  8. The six core elements of health care transition 3.0. Got Transition. Accessed April 11, 2024.
  9. Sandquist M, Davenport T, Monaco J, Lyon ME. The transition to adulthood for youth living with rare diseases. Children (Basel). 2022;9(5):710.
  10. Fisher MJ, Blakeley JO, Weiss BD, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol. 2022;24(11):1827-1844.
  11. Higham CS, Dombi E, Rogiers A, et al. The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors. Neuro Oncol. 2018;20(6):818-825.
  12. Miettinen MM, Antonescu CR, Fletcher CDM, et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1—a consensus overview. Hum Pathol. 2017;67:1-10.
  13. Zehou O, Fabre E, Zelek L, et al. Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review. Orphanet J Rare Dis. 2013;8:127.
  14. Fournier H, Calcagni N, Morice-Picard F, Quintard B. Psychosocial implications of rare genetic skin diseases affecting appearance on daily life experiences, emotional state, self-perception and quality of life in adults: a systematic review. Orphanet J Rare Dis. 2023;18(1):39.
  15. Radtke HB, Klein-Tasman BP, Merker VL, et al. The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research. Orphanet J Rare Dis. 2021;16(1):61.